B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8

Benzinga Newsdesk www.benzinga.com Negative 64.7%

Neg 64.7% Neu 0% Pos 0%

B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.